Recently, I reported on the positive results of iniparib, a PARP inhibitor, for treating metastatic triple-negative breast cancer. Sadly, further investigation has reported results that iniparib fails to extend survival at a statistically significant rate even though it extends overall survival by five months. The investigators will report the data at upcoming national and international conferences of clinical oncologists.
5 6 7 8
© 2004–2011 Donna Peach. All rights reserved.